Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma

Kenji Inoue,1 Ayumi Tanaka,1 Goji Tomita2 1Inouye Eye Hospital, 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan Purpose: To evaluate the effects of tafluprost treatment for 3 years on intraocular pressure (IOP) and visual field performance. Methods: The IOP of 55 p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue K, Tanaka A, Tomita G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/20753fe15df84bc19bafaf9d33752fa6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:20753fe15df84bc19bafaf9d33752fa6
record_format	dspace
spelling	oai:doaj.org-article:20753fe15df84bc19bafaf9d33752fa62021-12-02T07:34:03ZEffects of tafluprost treatment for 3 years in patients with normal-tension glaucoma1177-54671177-5483https://doaj.org/article/20753fe15df84bc19bafaf9d33752fa62013-07-01T00:00:00Zhttp://www.dovepress.com/effects-of-tafluprost-treatment-for-3-years-in-patients-with-normal-te-a13615https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Kenji Inoue,1 Ayumi Tanaka,1 Goji Tomita2 1Inouye Eye Hospital, 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan Purpose: To evaluate the effects of tafluprost treatment for 3 years on intraocular pressure (IOP) and visual field performance. Methods: The IOP of 55 patients with normal-tension glaucoma was monitored every 1–3 months for 3 years. The Humphrey visual field test was performed every 6 months after treatment and results compared with before-treatment results. Visual field performance was also evaluated by trend and event analysis. Results: After 3 years’ tafluprost single-use vials treatment, the IOP (12.8 ± 2.8 mmHg [mean ± standard deviation]) was significantly lower than before treatment (15.7 ± 2.2 mmHg; P < 0.0001). When comparing before-treatment Humphrey visual field test findings with those after 3 years of treatment, no change was found in the mean deviation and pattern standard deviation. Visual field performance had worsened in four patients and three patients according to trend analysis and event analysis, respectively. Adverse reactions appeared in ten cases and one patient (1.8%) discontinued treatment due to an adverse reaction. Conclusion: Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%–13.8% in patients with normal-tension glaucoma. Safety was satisfactory. Keywords: intraocular pressure, visual field, trend analysis, event analysisInoue KTanaka ATomita GDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 1411-1416 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Inoue K Tanaka A Tomita G Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
description	Kenji Inoue,1 Ayumi Tanaka,1 Goji Tomita2 1Inouye Eye Hospital, 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan Purpose: To evaluate the effects of tafluprost treatment for 3 years on intraocular pressure (IOP) and visual field performance. Methods: The IOP of 55 patients with normal-tension glaucoma was monitored every 1–3 months for 3 years. The Humphrey visual field test was performed every 6 months after treatment and results compared with before-treatment results. Visual field performance was also evaluated by trend and event analysis. Results: After 3 years’ tafluprost single-use vials treatment, the IOP (12.8 ± 2.8 mmHg [mean ± standard deviation]) was significantly lower than before treatment (15.7 ± 2.2 mmHg; P < 0.0001). When comparing before-treatment Humphrey visual field test findings with those after 3 years of treatment, no change was found in the mean deviation and pattern standard deviation. Visual field performance had worsened in four patients and three patients according to trend analysis and event analysis, respectively. Adverse reactions appeared in ten cases and one patient (1.8%) discontinued treatment due to an adverse reaction. Conclusion: Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%–13.8% in patients with normal-tension glaucoma. Safety was satisfactory. Keywords: intraocular pressure, visual field, trend analysis, event analysis
format	article
author	Inoue K Tanaka A Tomita G
author_facet	Inoue K Tanaka A Tomita G
author_sort	Inoue K
title	Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
title_short	Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
title_full	Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
title_fullStr	Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
title_full_unstemmed	Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
title_sort	effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/20753fe15df84bc19bafaf9d33752fa6
work_keys_str_mv	AT inouek effectsoftafluprosttreatmentfor3yearsinpatientswithnormaltensionglaucoma AT tanakaa effectsoftafluprosttreatmentfor3yearsinpatientswithnormaltensionglaucoma AT tomitag effectsoftafluprosttreatmentfor3yearsinpatientswithnormaltensionglaucoma
_version_	1718399324807757824

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma

Ejemplares similares